AngioDynamics (ANGO) Competitors

AngioDynamics (NASDAQ:ANGO) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings.

Is ANGO or ATEC more profitable?

Alphatec has a net margin of -31.06% compared to AngioDynamics' net margin of -79.38%. AngioDynamics' return on equity of -7.26% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-79.38%	-7.26%	-4.78%
Alphatec	-31.06%	-541.39%	-22.99%

Which has more risk & volatility, ANGO or ATEC?

AngioDynamics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.

Which has preferable valuation and earnings, ANGO or ATEC?

AngioDynamics has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$303.91M	1.38	-$184.35M	-$5.63	-1.83
Alphatec	$482.26M	3.12	-$186.64M	-$1.28	-8.29

Does the MarketBeat Community prefer ANGO or ATEC?

AngioDynamics received 37 more outperform votes than Alphatec when rated by MarketBeat users. Likewise, 61.19% of users gave AngioDynamics an outperform vote while only 57.94% of users gave Alphatec an outperform vote.

Company	Underperform	Outperform
AngioDynamics	Outperform Votes 369 61.19%	Underperform Votes 234 38.81%
Alphatec	Outperform Votes 332 57.94%	Underperform Votes 241 42.06%

Do analysts prefer ANGO or ATEC?

AngioDynamics presently has a consensus price target of $13.00, indicating a potential upside of 25.85%. Alphatec has a consensus price target of $17.56, indicating a potential upside of 65.46%. Given Alphatec's higher possible upside, analysts clearly believe Alphatec is more favorable than AngioDynamics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alphatec	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Do institutionals & insiders have more ownership in ANGO or ATEC?

89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 66.4% of Alphatec shares are owned by institutional investors. 5.4% of AngioDynamics shares are owned by company insiders. Comparatively, 22.8% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media prefer ANGO or ATEC?

In the previous week, Alphatec had 3 more articles in the media than AngioDynamics. MarketBeat recorded 4 mentions for Alphatec and 1 mentions for AngioDynamics. Alphatec's average media sentiment score of 0.80 beat AngioDynamics' score of 0.77 indicating that Alphatec is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alphatec	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alphatec beats AngioDynamics on 10 of the 18 factors compared between the two stocks.